MOGAT2 catalyzes the formation of diacylglycerol from monoacylglycerol and fatty acyl-CoA, serving as a key enzyme in triacylglycerol synthesis and dietary fat absorption in the small intestine. The enzyme preferentially processes monoacylglycerols containing unsaturated fatty acids and can also utilize ether-linked lipid precursors for synthesis of specialized lipid species. Beyond its classical role in intestinal lipid resynthesis, MOGAT2 has emerged as a metabolic regulator with context-dependent roles in disease. In lung adenocarcinoma, MOGAT2 was identified as a potential anti-tumor regulator; MOGAT2 knockdown promoted proliferation and migration in cultured cells, while higher expression correlated with improved survival and enhanced anti-PD-1 immunotherapy response 1. Conversely, in colorectal cancer, MOGAT2 functions as a tumor suppressor by inhibiting proliferation and invasion through ACSM1-mediated lipid metabolic reprogramming 2. Recent studies have identified MOGAT2 as a therapeutic target for metabolic diseases; the MOGAT2 inhibitor VB-87531 induced weight loss in obese mice and synergized with tirzepatide and semaglutide for enhanced metabolic improvements 3. Additionally, MOGAT2 has been identified as a host dependency factor for hepatitis B virus replication, with MOGAT2 inhibition impairing viral transcription 4. Intestine-specific MOGAT2 deletion protects mice from diet-induced obesity and glucose intolerance by increasing energy expenditure 5, establishing intestinal lipid metabolism as a feasible intervention target for metabolic disease.